Type 2 Diabetes, Metabolic traits and Risk of Heart Failure:a Mendelian Randomization study by Mordi, Ify et al.
                                                                    
University of Dundee
Type 2 Diabetes, Metabolic traits and Risk of Heart Failure










Link to publication in Discovery Research Portal
Citation for published version (APA):
Mordi, I., Lumbers, R. T., Palmer, C. N. A., Pearson, E. R., Sattar, N., Holmes, M. V., Lang, C. C., & HERMES
Consortium (2021). Type 2 Diabetes, Metabolic traits and Risk of Heart Failure: a Mendelian Randomization
study. Diabetes Care, [dc202518]. https://doi.org/10.2337/dc20-2518
General rights
Copyright and moral rights for the publications made accessible in Discovery Research Portal are retained by the authors and/or other
copyright owners and it is a condition of accessing publications that users recognise and abide by the legal requirements associated with
these rights.
 • Users may download and print one copy of any publication from Discovery Research Portal for the purpose of private study or research.
 • You may not further distribute the material or use it for any profit-making activity or commercial gain.
 • You may freely distribute the URL identifying the publication in the public portal.
Take down policy
If you believe that this document breaches copyright please contact us providing details, and we will remove access to the work immediately
and investigate your claim.
Download date: 11. Jun. 2021
1 
 
Type 2 Diabetes, Metabolic traits and Risk of Heart Failure: a Mendelian Randomization study 
Ify R Mordi MD1, R Thomas Lumbers PhD2, Colin NA Palmer PhD3, Ewan R Pearson PhD3, Naveed 
Sattar PhD4, Michael V Holmes PhD5*, Chim C Lang MD1* on behalf of the HERMES Consortium 
*Equal Contribution 
1. Division of Molecular and Clinical Medicine, University of Dundee, Dundee, United Kingdom 
2. Institute of Health Informatics, University College London, London, United Kingdom. 
3. Division of Population Health and Genomics, University of Dundee, Dundee, United Kingdom 
4. Institute of Cardiovascular and Medical Sciences, University of Glasgow, Glasgow, United Kingdom 
5. Clinical Trial Service Unit & Epidemiological Studies Unit, Nuffield Department of Population Health, 
University of Oxford, Oxford, United Kingdom 
Corresponding Author: Dr Ify Mordi, Division of Molecular and Clinical Medicine, University of 
Dundee, Dundee, United Kingdom. 
E-mail: i.mordi@dundee.ac.uk 
Telephone: +44 1382 383106 
Fax: +44 1382 383259  
Word Count: 3,984 
Number of Tables and Figures: 2 





The aim of this study was to use Mendelian randomization (MR) techniques to estimate the causal 
relationships between genetic liability to type 2 diabetes, glycaemic traits and risk of HF. 
Research Design and Methods 
Summary-level data were obtained from genome-wide association studies (GWAS) of type 2 diabetes, 
insulin resistance (IR), glycated haemoglobin, fasting insulin and glucose and HF. MR was conducted 
using the inverse variance weighted (IVW) method. Sensitivity analyses included MR-Egger, weighted 
median and mode methods, and multivariable MR conditioning on potential mediators. 
Results 
Genetic liability to type 2 diabetes was causally related to higher risk of HF (OR: 1.13 per 1 log-unit 
higher risk of type 2 diabetes; 95% CI 1.11-1.14, p<0.001), however sensitivity analysis revealed 
evidence of directional pleiotropy. The relationship between type 2 diabetes and HF was attenuated when 
adjusted for coronary disease, body mass index, LDL-cholesterol and blood pressure. Genetically-
instrumented higher IR was associated with higher risk of HF (OR 1.19 per 1 log-unit higher risk of IR; 
95% CI 1.00-1.41, p=0.041). There were no notable associations identified between fasting insulin, 
glucose or glycated haemoglobin and risk of HF. Genetic liability to HF was causally linked to higher risk 
of type 2 diabetes (OR 1.49; 95% CI 1.01-2.19, p=0.042) though again with evidence of pleiotropy. 
Conclusions 
These findings suggest a causal role of type 2 diabetes and IR in HF aetiology, though both the presence 




Type 2 diabetes and heart failure (HF) are increasingly common scourges. The worldwide prevalence of 
type 2 diabetes is almost 10%(1) while the estimated prevalence of HF is 2.2% in the United States.(2) 
While type 2 diabetes and HF frequently co-exist, their causal inter-relationship is poorly understood. 
Observational studies have shown that patients with type 2 diabetes have a 2 to 3-fold increased risk of 
developing HF compared to individuals without type 2 diabetes independent of other risk factors such as 
coronary heart disease; the prevalence of HF at baseline in recent type 2 diabetes clinical trials has ranged 
from 10-30%.(3) Glycaemic traits related to type 2 diabetes, such as insulin resistance (IR)(4; 5) and 
glycated haemoglobin (HbA1c)(6) have also been independently associated with incident HF. There is 
some suggestion that the relationship might be bidirectional with HF being associated with higher 
likelihood of type 2 diabetes development, although this has been less easy to evaluate given 
confounding. HF patients appear to have a higher prevalence of type 2 diabetes than the general 
population (3) and a higher prevalence of IR.(7) 
Observational analyses cannot provide evidence of causality and whether type 2 diabetes causes heart 
failure remains uncertain. Randomised controlled trials of interventions of glucose-lowering therapies 
have reported inconsistent effects on incident HF, and until recently, with sodium-glucose co-transporter 
2 (SGLT2) inhibitors, treatment of type 2 diabetes had not been shown to reduce HF risk(8). It is possible 
that observational associations between type 2 diabetes and HF simply reflect associations with other 
prevalent upstream risk factors such as coronary heart disease, obesity and hypertension. 
Mendelian randomisation (MR) uses data from genetic studies to estimate the unconfounded relationships 
between exposures and outcomes. By using genetic variants associated with exposures, the causal effect 
of the exposure on an outcome excluding confounders can be estimated.(9; 10) Multivariable MR 
techniques can also be used to take into account potential pleiotropic effects of genetic variants to 
estimate direct effects.(11)  
The aim of this study was to use MR techniques to shed light on the relationships of metabolic risk factors 





Two-sample MR was performed using published summary-level data from GWASs of the traits of 
interest in predominantly European individuals. Details of the GWAS datasets are given in 
Supplementary Table 1. Exposures of interest were type 2 diabetes, insulin resistance, HbA1c, fasting 
insulin, fasting glucose and HF. For type 2 diabetes, we used two GWAS datasets. First, we selected 529 
variants significantly (at p<5x10-8) associated with type 2 diabetes from a GWAS from the DIAMANTE 
consortium of 228,499 type 2 diabetes cases and 1,178,783 controls (Supplementary Table 2).(12) T2D 
cases were variably defined using physician diagnosis, self-reported use of T2D medications, elevated 
fasting glucose or glycated haemoglobin or ICD coding, either alone or in combination, as described in 
the main GWAS papers. We were unable to obtain summary-level data for the DIAMANTE GWAS, so in 
order to perform multivariable MR analyses we used an earlier T2D GWAS from the DIAGRAM 
consortium of 74,124 T2D cases and 824,006 controls of European ancestry, selecting 234 variants 
associated with T2D at GWAS significance (Supplementary Table 3).(13) Variants associated with 
insulin resistance were obtained from a GWAS of 188,577 individuals published by the Meta-Analyses of 
Glucose and Insulin-related traits Consortium (MAGIC).(14) In the MAGIC GWAS, the authors 
identified variants associated with the combined phenotype of higher fasting insulin and triglyceride 
levels and lower HDL-cholesterol. Because this study did not publish beta estimates and standard errors 
for the association of each SNP with a combined IR phenotype, these were obtained from a subsequent 
MR study (Supplementary Table 4).(15) Variants associated with the individual traits fasting insulin, 
fasting glucose and HbA1c were also obtained from GWAS published by the MAGIC investigators 
(Supplementary Table 5-7).(16; 17)  
Variants associated with HF were obtained from a GWAS of 47,309 cases and 930,014 controls published 
by the Heart Failure Molecular Epidemiology for Therapeutic Targets (HERMES) consortium 
(Supplementary Table 8).(18) This GWAS included HF samples from population cohorts and case-
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control studies. The full details of each contributing cohort have been published previously. To identify 
HF cases, of the 25 participating studies, physician diagnosis of HF was used by 18 cohorts, ICD coding 
for HF by 12, imaging by 15, HF treatment by 8 and natriuretic peptides by one cohort. 20 of the 25 
cohorts used a combination of at least two of these diagnostic criteria, while the remaining 5 studies used 
ICD coding alone.  
An observational estimate of the association between type 2 diabetes and incident HF was performed 
using individual level data from the Genetics of Diabetes Audit and Research Tayside Scotland 
(GoDARTS) study, the details of which have been published previously.(19) Briefly, GoDARTS is a 
cohort study including 10,149 patients with type 2 diabetes and 8,157 controls without type 2 diabetes. 
All patients provided a blood sample for genotyping at the recruitment to the study and consented for 
follow-up using electronic health record linkage. Diagnosis of HF cases was made where the ICD-10 code 
for HF (I50) was present within the first three causes of death or hospitalisation.(20) Deaths and 
hospitalisations were obtained from the General Register Office for Scotland (GRO) and the Scottish 
Morbidity Record (SMR) 01 respectively. This was supplemented by echocardiographic data from the 
electronic health record showing reduced left ventricular systolic function (where this had been performed 
for clinical reasons) and the requirement for loop diuretic treatment.  
MR in the reverse direction was also performed to evaluate the association between HF and type 2 
diabetes. For this analysis, SNPs associated with HF at GWAS significance in the HERMES GWAS were 
used as the exposure. Variants from the DIAGRAM GWAS were used as the outcome for the estimate of 
the association between HF and type 2 diabetes.(13) 
Individuals participating in each of the GWAS consortia provided ethical approval to take part in the 
contributing studies as such no specific ethical approval was required for this study. Summary-level data 




First, an observational analysis was performed using data from the GoDARTS study to determine the 
association between type 2 diabetes and HF incidence. We performed multivariable Cox proportional 
hazards regression with adjustment for age, sex, systolic blood pressure, body mass index (BMI), 
smoking status, prior history of MI, aspirin and statin use and total and HDL cholesterol (as LDL 
cholesterol is not routinely reported in this cohort). A mediation analysis was also performed using the 
psych R package to determine how much of the association between T2D and HF was mediated via prior 
MI, systolic blood pressure, HDL cholesterol, BMI, age and sex. 
We performed MR studies to determine the association between glycaemic traits and the development of 
HF, and in the reverse direction to evaluate the association between HF and development of type 2 
diabetes. Genetic variants associated with the exposure of interest at GWAS significance were selected as 
genetic instruments for each exposure. Variants were harmonized such that the effect allele was consistent 
across all datasets and was positively associated with the exposure traits. We pruned the genetic variants 
for those in linkage disequilibrium (r2 >0.01) by only including the variant with the strongest association 
with the exposure trait of interest. Palindromic variants were identified and corrected using allele 
frequencies where possible, with exclusion of variants where the major allele frequency was >45% and 
thus strand orientation could not be reliably ascertained.  
Throughout the manuscript, the MR estimate is expressed as an odds ratio with 95% confidence intervals. 
The primary analysis was performed using the inverse variance-weighted (IVW) method, whereby the 
genetic variant to outcome estimate is regressed on the variant to exposure estimate. IVW can give a 
biased estimate if the genetic instrument is invalid,(21) hence we also performed sensitivity tests using 1. 
The MR-Egger method, which is valid even if all variants are invalid, 2. The weighted median method, 
which provides a consistent estimate even when up to 50% of the information is from invalid instrumental 
variables and; 3. The weighted mode which produces robust estimates when the largest number of similar 
individual-instrument causal effect estimates arise from valid instruments, even if the most are 
invalid.(21-23) We also performed additional tests using the Lasso method which removes significant 
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outliers, and the MR‐Pleiotropy Residual Sum and Outlier (PRESSO) method which downgrades 
outliers.(24) We performed a leave-one-out analysis to determine whether any one single variant was 
driving the association between T2D and HF. Previous GWAS of IR have identified that although the 
majority of genetic variants contribute equally to the insulin resistance phenotype, rs1011685 (near the 
LPL gene) has a much weaker effect on fasting insulin when adjusted for BMI, therefore we also 
performed a sensitivity analysis excluding the variant in our genetic instrument for the effect of IR on 
HF.(15)  To formally assess the risk of bias due to sample overlap we performed a formal calculation of 
the F statistic using the method proposed by Burgess et al (https://sb452.shinyapps.io/overlap).(25) 
To further explore potential pleiotropic effects of the exposure on the outcome, we also conducted a 
multivariable MR analysis.(11) This method takes into account the association of variants with multiple 
exposures to clarify the direct effects (i.e. the effects that are not mediated by other traits included in the 
model) of exposures on outcomes. We performed multivariable MR using the IVW method for the 
association between type 2 diabetes and HF adjusted for effects of variants associated with BMI (26), 
LDL-cholesterol (27), systolic blood pressure (SBP) (28) and coronary heart disease (CHD).(29) We also 
performed sensitivity analyses using multivariable median and multivariable MR-Egger methods. Power 
calculations for our main analyses were performed using the method of Brion et al.(30) Overall, the 
DIAMANTE GWAS found genetic variants accounting for around 20% of the estimated heritability of 
T2D. As we only used genetic variants reaching GWAS significance for our MR analyses (as opposed to 
the whole genome), we conservatively estimated that our MR instrument would account for half of this 
(i.e. 10% proportion of variance in T2D risk). For the association from T2D to HF, we had >99% power 
to detect an association with an odds ratio of 1.1 at an alpha of 0.05. Even at a more conservative 
proportion of variance estimate of 2.5%, we still had >90% to detect an association with an odds ratio of 
1.1. For the association from HF to T2D, based on HF variants explaining 8.8% of the risk of HF, we also 
had >99% power to detect an association with an odds ratio of 1.1 at an alpha of 0.05. Supplementary 
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Figure 1 gives a visual representation of power calculations for a range of possible exposure instruments 
and odds ratios. 
All analyses were performed using R version 3.5.1. (R Foundation for Statistical Computing, Vienna, 
Austria) and the packages “MendelianRandomization” and “TwoSampleMR”. 
RESULTS 
Observational Association between Type 2 Diabetes and Heart Failure 
12,919 individuals were evaluated from the GoDARTS study including 8,329 (64.5%) with type 2 
diabetes. Baseline characteristics are summarised in Supplementary Table 9. Over a median follow-up 
of 10 years there were 1,293 incident HF events. The incidence of HF was higher in type 2 diabetes 
individuals than in controls without type 2 diabetes (13.4% vs. 3.9%). After adjustment for clinical 
variables including age, sex, systolic blood pressure, prior history of MI, BMI, aspirin and statin use and 
total and HDL cholesterol, type 2 diabetes was associated with a higher risk of developing HF (HR 1.40; 
95% CI 1.04-1.89, p=0.028). In mediation analysis approximately 35% of the association between T2D 
and HF was mediated via age, sex, history of prior MI, BMI, SBP and HDL cholesterol. 
Genetic Association between Type 2 Diabetes and Heart Failure 
Univariable MR analysis supported a causal role for liability to type 2 diabetes in the development of HF 
(IVW: DIAMANTE: 1.13 per 1 log-unit higher risk of type 2 diabetes; 95% CI 1.11-1.14, p<0.001; 
DIAGRAM: OR 1.06; 95% CI 1.03-1.09, p<0.001), however under sensitivity analyses, some estimates 
were attenuated: weighted median (DIAMANTE: OR 1.05; 95% CI 1.03-1.07, p=0.014 ; DIAGRAM: OR 
1.03; 95% CI 0.99-1.07, p=0.13), weighted mode (DIAMANTE: OR 1.03; 95% CI 1.00-1.06, p=0.30; 
DIAGRAM: OR 1.01; 95% CI 0.98-1.05, p=0.46), Lasso method (DIAMANTE: OR 1.12; 95% CI 1.09-
1.14, p<0.001; tuning parameter 0.08; DIAGRAM: OR 1.05; 95% CI 1.03-1.07, p<0.001; tuning 
parameter 0.11). The estimate from MR-Egger (DIAMANTE: OR 0.99; 95% CI 0.96-1.01, p=0.60; 
DIAGRAM: OR 0.99; 95% CI 0.94-1.04, p=0.62) was imprecise and provided additional evidence that 
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the variants used to instrument type 2 diabetes demonstrated unbalanced horizontal pleiotropy (intercept 
beta DIAMANTE: 0.006, se 0.001, p<0.001; DIAGRAM: 0.005, se 0.002, p<0.001) (Figure 1 and 
Supplementary Figure 2), also seen using the MR-PRESSO (DIAMANTE: estimate 1.13; 95% CI 1.10-
1.14, p<0.001; global test p<0.001), although there were no outliers. Using the CAUSE model also 
suggested that there was pleiotropy (causal model OR 1.04; 95% CI 1.00-1.08, p=0.07, difference in fit 
between causal model and sharing model -0.35, p=0.43). Leave-one-out analysis did not suggest that any 
one single variant was driving the association between T2D and HF (Supplementary Table 10). Formal 
assessment revealed minimal risk of relative bias (<0.01 regardless of overlap proportion), with an F 
statistic of 44.35. 
Despite this evidence of horizontal pleiotropy, we explored the extent to which the IVW estimate was 
driven by shared risk factors. Multivariable MR revealed that the association between genetic liability to 
type 2 diabetes and HF was most attenuated when adjusted for CHD but persisted (OR 1.04; 95% CI 
1.01-1.07, p=0.004). The association between type 2 diabetes and HF was similar to the unadjusted 
estimate when adjusted for BMI (OR 1.06; 95% CI 1.03-1.09, p<0.001); SBP (OR 1.05; 95% CI 1.02-
1.07, p<0.001) or LDL-cholesterol alone (OR 1.06; 95% CI 1.03-1.09, p=0.001). In a full model 
including the type 2 diabetes variants associations with CHD, SBP, BMI and LDL-cholesterol in 
multivariable MR, there was attenuation of the association between type 2 diabetes and HF (OR 1.03; 
95% CI 1.00-1.06, p=0.038), suggesting that around half of the genetic association between type 2 
diabetes and HF was explained via the association between type 2 diabetes and these traits (Figure 2, 
Supplementary Table 11). As with the univariable estimate, in sensitivity analyses there was some 
evidence of pleiotropy using the multivariable median method (OR 1.02; 95% CI 0.99-1.05, p=0.18). 
Using the multivariable MR-Egger the estimate was in the same direction as the IVW estimate (OR 1.02; 
95% CI 0.98-1.06, p=0.33), with no evidence of horizontal pleiotropy (intercept beta 0.001; 95% CI -
0.001-0.003, p=0.29).  
Genetic Association between Insulin Resistance, Glycaemic Traits and Heart Failure 
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MR results for the association of IR with HF are summarized in Figure 2. In univariate analysis 
genetically instrumented IR was related to a higher risk of HF using (IVW OR per 1-standard deviation 
higher IR 1.19; 95% CI 1.00-1.41, p=0.041), which remained the case using the weighted median method: 
OR 1.31; 95% CI 1.08-1.59, p=0.006). Consistent estimates were derived using the mode-based method 
(OR 1.21; 95% CI 0.99-1.50, p=0.06) and MR-Egger (OR 1.40; 95% CI 0.95-1.98, p=0.053) with no 
evidence of pleiotropy (intercept beta -0.004, 95% CI -0.012–0.013, p value 0.29) (Figure 2 and 
Supplementary Figure 3). In the sensitivity analysis excluding rs1011685 the IVW estimate for the 
causal association of IR on HF was attenuated (though directionally similar; OR 1.15; 95% CI 0.94-1.39, 
p=0.17).  
We identified no convincing evidence of causal relationships between genetically-instrumented fasting 
insulin and HF (IVW: OR 0.87 per 1-log unit increase in mmol/l fasting insulin; 95% CI 0.63-1.19, 
p=0.38); fasting glucose and HF (IVW: OR 0.99 per 1-log unit increase in mmol/l fasting glucose; 95% 
CI 0.66-1.51, p=0.98) or HbA1c and HF (IVW: OR 1.00 per 1-log-unit % higher HbA1c; 95% CI 0.80-
1.25, p=0.99). 
Genetic Association between Heart Failure and Type 2 Diabetes 
Using the IVW method, genetic liability to HF was related to a higher risk of type 2 diabetes (OR 1.49 per 
1-log unit increase in the relative odds of HF; 95% CI 1.01-2.19, p=0.042). Consistent measures of effect 
were identified using weighted median (OR 1.31; 95% CI 1.15-1.51, p<0.001) but more weakly using the 
mode-based estimate (OR 1.15; 95% CI 0.98-1.35, p=0.08). MR-Egger demonstrated potential evidence 
of horizontal pleiotropy, with imprecise causal estimates and a reversal of the point estimate (OR 0.57; 
95% CI 0.20-1.64, p=0.30, intercept beta 0.064, p=0.059) (Supplementary Figure 4). 
DISCUSSION 
In this Mendelian randomization study, we found evidence in potential support of causal roles of genetic 
liability to type 2 diabetes and insulin resistance with HF. In both cases, the relationships attenuated when 
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we included CAD in the analyses, suggesting that the causal effects, if real, might be partially mediated 
by CAD. We found potential evidence of a bidirectional relationship between HF and risk of type 2 
diabetes, which, together with evidence of directional pleiotropy potentially undermines the strength and 
presence of this relationship. We did not find any association between genetic determinants of fasting 
insulin, fasting glucose or HbA1c and HF. These findings shed additional light on the relationships 
between type 2 diabetes, IR and HF and support the importance of the prevention of CAD in patients with 
type 2 diabetes to prevent development of HF. 
Several observational studies have reported an association between type 2 diabetes and HF.(31) Similarly, 
IR has also been associated with HF in observational studies.(4) Our MR study has shown that there is a 
relationship between genetic variants predisposing to type 2 diabetes and HF. Although in univariate 
analysis we did show presence of causal effects between both type 2 diabetes and IR and risk of HF, this 
association was attenuated when we adjusted for the genetic association with coronary heart disease. We 
also found evidence of directional pleiotropy in the relationship between genetic variants associated with 
type 2 diabetes and HF within our analyses. This may reflect the shared pathophysiological pathways 
between type 2 diabetes and CHD, and CHD and HF, and/or suggests the potential presence of bias in our 
MR analysis. It is notable that in our multivariable MR analysis the MR-Egger intercept included zero, 
suggesting that inclusion of genetic variants associated with CHD, systolic blood pressure, BMI and 
LDL-cholesterol at least in part explain some of this directional pleiotropy. Genetic variants associated 
with type 2 diabetes are strongly associated with CHD(32), while genetic variants associated with CHD 
are strongly associated with HF.(18) If CHD is the primary cause of HF in these patients then this would 
explain the attenuation of the results, reflecting the shared pathophysiological pathways between type 2 
diabetes, CHD and HF. We also found an association between IR and HF, and no evidence of directional 
pleiotropy, although this was driven by a variant near the LPL gene (rs1011685). The associations 
between type 2 diabetes and HF may, at least in part, be indirect, mediated by the associations between 
metabolic disease and coronary heart disease.  
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We recognise that CHD risk is already elevated before T2D develops.  Indeed, we recently showed that 
people with pre-diabetes had a higher cardiovascular risk profile than those with normal glycaemic 
control.(33) By taking BMI, SBP and LDL cholesterol into account, we have considered most of the 
relevant factors in our analyses. The presence of pleiotropy in our results does however mean that we 
cannot be completely certain that genetic associations between HF and T2D are not mediated via 
alternative, non-direct pathways. 
We found that the relationship between type 2 diabetes and HF was attenuated by SBP. Hypertension is 
particularly prevalent in patients with insulin resistance(34), and both type 2 diabetes and IR are 
associated with development of left ventricular hypertrophy, a precursor of HF. The fact that the genetic 
relationship between type 2 diabetes and HF was only partially attenuated by SBP might reflect our 
increasing understanding that T2D is actually comprised of distinct clusters of patients in whom IR is not 
always the underlying pathophysiological problem.(35) In addition, IR is in part downstream of other 
processes, such as ectopic fat deposition.(36) 
We found no evidence for a causal relationship between fasting insulin, fasting glucose or HbA1c and 
risk of HF. It is probable that dysglycaemia alone does not explain the increased incidence of HF in type 2 
diabetes patients. It is likely that the benefits of type 2 diabetes therapies such as SGLT2 inhibitors on HF 
are by mechanisms other than improved glycaemic control.(37) Importantly however the genetic variants 
associated with fasting insulin and glucose and glycated haemoglobin we used in our analyses only 
account for a small proportion of the variance in these parameters and so we may have been 
underpowered to detect a smaller but significant effect, such has been seen in traditional observational 
data.  
Our finding that genetic liability to HF is associated with type 2 diabetes risk is also of interest. Although 
the presence of HF as a risk factor for incident type 2 diabetes per se has not been previously evaluated, 
HF patients have a high prevalence of type 2 diabetes and dysglycaemia (although this could reflect the 
causal role of type 2 diabetes in HF). In HF clinical trial populations the prevalence of type 2 diabetes was 
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up to 40%.(3) In the Candesartan in Heart Failure Assessment of Reduction in Mortality and Morbidity 
(CHARM) trial 7.8% of patients developed new onset type 2 diabetes over the median 2.8 year follow-up 
period.(38) Observational data suggest that HF patients with more severe symptoms are more likely to 
develop type 2 diabetes.(39) HF has also been strongly associated with generalised insulin resistance, 
however whether this association is simply a reflection of the high prevalence of type 2 diabetes and 
prediabetes in HF populations(40) is unclear. Our findings might lend support to a causal relationship 
between liability to HF and increased risk of type 2 diabetes. 
There are some limitations with our study. First, this analysis was conducted with summary-level data, 
limiting our ability to perform subgroups analysis, for example by age or sex. Second, we cannot exclude 
non-linear relationships between (for example) glycated haemoglobin and HF, as has been reported in 
previous observational studies.(6) The genetic variants selected in our MR analyses may not account for 
all of the genetic variation in examined traits and we may have been underpowered to find a small but 
statistically significant effect, for example in relation to the association between fasting insulin levels and 
HF, as the fasting insulin GWAS only included a few genetic variants and likely only accounts for a small 
proportion of the variation of fasting insulin levels. Nevertheless, we were adequately powered for our 
main analyses. Third, we did not have any HF subtype data available, for example HF with reduced 
versus preserved ejection fraction, or ischaemic versus non-ischaemic aetiology. It is likely that the 
relationship between T2D and HF is different between aetiologies or across the left ventricular ejection 
fraction spectrum, and this should be the focus of further work. Similarly, recent studies have identified 
genetic variants relating to specific clusters of pathophysiological subtypes of T2D (e.g. beta cell 
function, obesity). At present these clusters have only included 20-30 variants for each subtype and so 
have limited power in MR studies, however as more genetic variants are discovered and these clusters 
become larger it may be possible to determine whether specific clusters of T2D variants are differentially 
associated with HF. Finally, the majority of patients in the GWAS used for this analysis were Caucasian, 




Our results suggest that genetic liability to type 2 diabetes and IR play a causal role in the aetiology of 
HF, and that CAD, in particular, might mediate this relationship. Presence of directional pleiotropy is 
however a concern and might be a source of bias. Further MR studies with sequential incidence of disease 
onset (between type 2 diabetes, CAD and HF) and HF subtypes e.g. preserved vs. reduced ejection 
fraction, will help to establish the exact nature of this relationship. 
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and Heart Failure. 
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